Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cipargamin + KLU156 in Uncomplicated Plasmodium Falciparum Malaria
NCT07811908Phase 2Recruiting
- Sponsor
- Novartis
- Start
- Feb 2026
- Primary completion
- Feb 2027
- Countries
- 7
01
Overview
A Phase 2 trial of cipargamin, ganaplacide + lumefantrine-SDF in Plasmodium falciparum malaria, sponsored by Novartis. Started Feb 2026; status: recruiting.
02
Drugs
cipargaminganaplacide + lumefantrine-SDF
03
Conditions
Plasmodium falciparum malaria
Beyond the preview
Go deeper on NCT07811908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07811908.